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The efficacy and safety of statin therapy are well estab-
lished. However, despite their favourable profile, muscle
symptoms reported with statin therapy limit their use neg-
atively impacting adherence and cardiovascular benefits of
this treatment. It is important that clinicians are cautious
before attributing muscle symptoms to statin therapy,
without further investigation of their cause. Moreover, this
is complicated by the lack of internationally agreed clinical
definitions of statin-induced myopathy and diagnostic
tools.
Recently the European Atherosclerosis Society (EAS)
Consensus Panel has circumvented the lack of consensus re-
garding the causality of statins with muscle symptoms by
the use of the term statin-associated muscle symptoms,
Table 1 Deﬁnition of statin-associated muscle symptoms from reference1
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SAMS (Table 1), thus providing an accessible resource for
the diagnosis, assessment, and management of SAMS, as
well as an update on current thinking about the aetiology
of statin myopathy.
Understanding and clearly defining is critical for optimal
treatment. Therefore, the management of SAMS is a key in
the effective treatment of patients with cardiovascular
disease (CVD), through achievement of maximum-
tolerated statin dosing and other practical aspects.
Combination therapy with ezetimibe and the addition of
Proprotein convertase subtilisin/kexin type 9 inhibitors in
high-risk patients with elevated LDL-C is supported by a
pharmacological and clinical evidence and is the logical ap-
proach tomaintain patients on statin therapy with the final
aim to optimize the cardiovascular benefits of this
treatment.
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